Barinthus Biotherapeutics plc. (BRNS)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$67.2M
Cash & Equivalents
$3.4M
Quarterly Burn Rate
60 mo
Est. Cash Runway
$26M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-11-01 Phase1 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06310291 VTP-1000 in Adults With Celiac Disease PHASE1 Recruiting 45

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BRNS.

SEC EDGAR Filings

All SEC filings for Barinthus Biotherapeutics plc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.